146 related articles for article (PubMed ID: 28419992)
1. Extended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience.
Gurevich-Shapiro A; Tzadok S; Rosenberg A; Inbal A; Bar-Natan M; Wolach O; Raanani P
Acta Haematol; 2017; 137(4):183-190. PubMed ID: 28419992
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval.
Cid J; Ramiro L; Escoda L; Llorente A
Vox Sang; 2009 Jan; 96(1):29-33. PubMed ID: 19121195
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions.
Anderson NA; Gray S; Copplestone JA; Chan DC; Hamon M; Prentice AG; Johnson SA; Phillips M; van Waeg G; Oakhill A; Abeyasekera S; Pamphilon DH
Transfus Med; 1997 Mar; 7(1):33-9. PubMed ID: 9089983
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy and safety of autologous cryopreserved platelet transfusion in management of thrombocytopenia after chemotherapy in hematological malignancy].
Liu GQ; Ding HF; Lu XJ; Xu M; Xing J; Zhao X; Han F; Shang YH
Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):188-91. PubMed ID: 22781890
[TBL] [Abstract][Full Text] [Related]
6. Platelet kinetics and decreased transfusion requirements after splenectomy for hematologic malignancy.
Berman RS; Feig BW; Hunt KK; Mansfield PF; Pollock RE
Ann Surg; 2004 Nov; 240(5):852-7. PubMed ID: 15492568
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
8. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study.
Pavenski K; Warkentin TE; Shen H; Liu Y; Heddle NM
Transfusion; 2010 Jul; 50(7):1552-60. PubMed ID: 20210928
[TBL] [Abstract][Full Text] [Related]
9. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial.
Lee EJ; Schiffer CA
Transfusion; 1989 Jun; 29(5):384-9. PubMed ID: 2660333
[TBL] [Abstract][Full Text] [Related]
10. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
11. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
12. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
Triulzi DJ; Assmann SF; Strauss RG; Ness PM; Hess JR; Kaufman RM; Granger S; Slichter SJ
Blood; 2012 Jun; 119(23):5553-62. PubMed ID: 22496156
[TBL] [Abstract][Full Text] [Related]
13. A positive effect of immune suppression on corrected count increment after platelet transfusion at 1 but not at 24h.
Dijkstra-Tiekstra MJ; Rondeel JM; Slomp J; Smid WM; de Wildt-Eggen J
Transfus Apher Sci; 2013 Oct; 49(2):189-92. PubMed ID: 23491866
[TBL] [Abstract][Full Text] [Related]
14. Post-transfusion increment of platelet count in thrombocytopenic patients treated with platelet concentrates.
Hoque MM; Rahman M; Rahman SM; Habibullah MM; Faruki MA; Rahman KH; Mamun AA; Hossain MA
Mymensingh Med J; 2013 Jan; 22(1):64-8. PubMed ID: 23416811
[TBL] [Abstract][Full Text] [Related]
15. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
[TBL] [Abstract][Full Text] [Related]
17. Patient and product factors affecting platelet transfusion results.
Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
[TBL] [Abstract][Full Text] [Related]
18. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
Stanworth SJ; Hyde C; Brunskill S; Murphy MF
Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
[TBL] [Abstract][Full Text] [Related]
19. Platelet function testing to assess effectiveness of platelet transfusion therapy.
Salama ME; Raman S; Drew MJ; Abdel-Raheem M; Mahmood MN
Transfus Apher Sci; 2004 Apr; 30(2):93-100. PubMed ID: 15062745
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
Slichter SJ; Davis K; Enright H; Braine H; Gernsheimer T; Kao KJ; Kickler T; Lee E; McFarland J; McCullough J; Rodey G; Schiffer CA; Woodson R
Blood; 2005 May; 105(10):4106-14. PubMed ID: 15692069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
